About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
PMID: 38114163 Journal: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER Year: 2023 Reference: Int J Gynecol Cancer. 2023 Dec 18:ijgc-2023-005109. doi: 10.1136/ijgc-2023-005109. Impact factor: Publication type: Paper in international publication Authors: Agusti, Nuria; Angeles, Martina Aida; Barreira-Diaz, Ana; Bilir, Esra; Bizzarri, Nicolo; Bonaldo, Giulio; Buti, Maria; Cucinella, Giuseppe; De Vitis, Luigi Antonio; du Bois, Andreas et al. DOI: 10.1136/ijgc-2023-005109
PMID: 38139013 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2023 Reference: Int J Mol Sci. 2023 Dec 6;24(24):17185. doi: 10.3390/ijms242417185. Impact factor: Publication type: Paper in international publication Authors: Adombi, Caroline Melanie; Buti, Maria; Campos, Carolina; Colomer-Castell, Sergi; Cortese, Maria Francesca; Esteban, Juan Ignacio; Garcia-Cehic, Damir; Gregori, Josep; Ibanez-Lligona, Marta; Quer, Josep et al. DOI: 10.3390/ijms242417185
PMID: 38147137 Journal: JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY Year: 2023 Reference: J Am Soc Nephrol. 2023 Dec 26. doi: 10.1681/ASN.0000000000000287. Impact factor: Publication type: Paper in international publication Authors: Abbadessa, Giovanni; Adombi, Caroline Melanie; Ali, Nicole; Bestard, Oriol; Brar, Amarpali; Buti, Maria; Campos, Carolina; Colomer-Castell, Sergi; Cortese, Maria Francesca; Cruzado, Josep M et al. DOI: 10.1681/ASN.0000000000000287
PMID: 38188336 Journal: Frontiers in Medicine Year: 2023 Reference: Front Med (Lausanne). 2023 Dec 20;10:1301001. doi: 10.3389/fmed.2023.1301001. eCollection 2023. Impact factor: Publication type: Paper in international publication Authors: Bajana, Ivan; Camos, Silvia; Castellanos, Sara; Chiscano-Camon, Luis; Corona, Pablo; Ferrer, Ricard; Ferrer-Costa, Roser; Joshi-Jubert, Nayana; Martin, Laura; Martin-Rodriguez, Cristina et al. DOI: 10.3389/fmed.2023.1301001
PMID: 32512213 Journal: Journal of Gynecology Obstetrics and Human Reproduction Year: 2021 Reference: J Gynecol Obstet Hum Reprod. 2021 Jan;50(1):101827. doi: 10.1016/j.jogoh.2020.101827. Epub 2020 Jun 5. Impact factor: Publication type: Paper in international publication Authors: Bonacina, Erika; Carreras, Elena; Castellote, Laura; Garcia-Manau, Pablo; Hurtado, Ivan; Lopez-Martinez, Rosa Maria; Martinez, Luisa; Mendoza, Manel; Serrano, Berta; Tur, Helena et al. DOI: 10.1016/j.jogoh.2020.101827
PMID: 33365252 Journal: Molecular Genetics and Metabolism Reports Year: 2021 Reference: Mol Genet Metab Rep. 2020 Dec 15;26:100690. doi: 10.1016/j.ymgmr.2020.100690. eCollection 2021 Mar. Impact factor: Publication type: Paper in international publication Authors: Arranz, Jose Antonio; Carnicer, Clara; Carreno, Lidia; de Las Heras, Javier; Del Toro, Mireia; Garcia-Arumi, Elena; Gort, Laura; Lasa-Aranzasti, Amaia; Miguel, Lucia Dougherty-de; Sala-Coromina, Julia et al. DOI: 10.1016/j.ymgmr.2020.100690
Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.
Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.
Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.
